Daniel S. Peeper
Impact in
- Oncology top 0.2%
- Cancer Immunotherapy and Biomarkers
- Cancer Cells and Metastasis
- Cutaneous Melanoma Detection and Management
- Cancer-related Molecular Pathways
- Physiology top 0.5%
- Telomeres, Telomerase, and Senescence
Papers in
- Oncology 60
- Cancer Immunotherapy and Biomarkers 33
- Cancer Cells and Metastasis 15
- Cancer-related Molecular Pathways 12
-
- Cancer, Hypoxia, and Metabolism 6
- Cancer Genomics and Diagnostics 6
- Co-authors
- Thomas Kuilman (19 shared papers)Wolter J. Mooi (5 shared papers)Chrysiis Michaloglou (4 shared papers)Liesbeth C.W. Vredeveld (4 shared papers)Benjamin D. Rowland (4 shared papers)Sirith Douma (7 shared papers)Thomas R. Geiger (6 shared papers)René Bernards (8 shared papers)
- Journals
- Nature (10 papers)Pigment Cell & Melanoma Research (7 papers)Cancer Cell (7 papers)Cancer Research (6 papers)Nature Cell Biology (5 papers)
- Partner nations
- NetherlandsUnited StatesUnited Kingdom
In The Last Decade
Daniel S. Peeper
140 papers receiving 19.7k citations
Daniel S. Peeper's Hit Papers
Peers
Comparison fields: 5 of 125
- Oncology 6.9k
- Physiology 3.3k
- Aging 193
- Cancer Research 1.6k
- Molecular Biology 6.3k
Countries citing papers authored by Daniel S. Peeper
This map shows the geographic impact of Daniel S. Peeper's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel S. Peeper with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel S. Peeper more than expected).
Fields of papers citing papers by Daniel S. Peeper
This network shows the impact of papers produced by Daniel S. Peeper. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel S. Peeper. The network helps show where Daniel S. Peeper may publish in the future.
Co-authors
The 25 scholars most cited alongside Daniel S. Peeper, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 142 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | B cells and tertiary lymphoid structures promote immunotherapy response Hit paper breakdown → | 2020 | 2032 |
| 2 | The human tumor microbiome is composed of tumor type–specific intracellular bacteria Hit paper breakdown → | 2020 | 1879 |
| 3 | BRAFE600-associated senescence-like cell cycle arrest of human naevi Hit paper breakdown → | 2005 | 1760 |
| 4 | Oncogene-Induced Senescence Relayed by an Interleukin-Dependent Inflammatory Network Hit paper breakdown → | 2008 | 1734 |
| 5 | Senescence-messaging secretome: SMS-ing cellular stress Hit paper breakdown → | 2009 | 761 |
| 6 | Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma Hit paper breakdown → | 2018 | 708 |
| 7 | Interrogating open issues in cancer precision medicine with patient-derived xenografts Hit paper breakdown → | 2017 | 547 |
| 8 | A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence Hit paper breakdown → | 2013 | 536 |
| 9 | 2004 | 504 | |
| 10 | 2014 | 495 | |
| 11 | 2005 | 483 | |
| 12 | 2005 | 462 | |
| 13 | Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial Hit paper breakdown → | 2019 | 426 |
| 14 | 2015 | 410 | |
| 15 | 2009 | 369 | |
| 16 | 1997 | 325 | |
| 17 | 2006 | 301 | |
| 18 | Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma Hit paper breakdown → | 2021 | 267 |
| 19 | Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma Hit paper breakdown → | 2021 | 265 |
| 20 | 2007 | 228 |
About Daniel S. Peeper
Daniel S. Peeper is a scholar working on Oncology, Cancer Research, Molecular Biology, Physiology and Immunology, having authored 142 papers that have together received 20k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (33 papers), Melanoma and MAPK Pathways (28 papers), Telomeres, Telomerase, and Senescence (25 papers), Cancer Cells and Metastasis (15 papers), Cancer-related Molecular Pathways (12 papers), Cancer, Hypoxia, and Metabolism (6 papers), Cancer Mechanisms and Therapy (6 papers) and Cancer Genomics and Diagnostics (6 papers). The work is most often cited by research in Oncology (6.9k citations), Physiology (3.3k citations), Aging (193 citations), Cancer Research (1.6k citations) and Molecular Biology (6.3k citations). Daniel S. Peeper has collaborated with scholars based in Netherlands, United States and United Kingdom. Frequent co-authors include Thomas Kuilman, Wolter J. Mooi, Chrysiis Michaloglou, Liesbeth C.W. Vredeveld, Benjamin D. Rowland, Sirith Douma, Thomas R. Geiger, René Bernards, Christophe J. Desmet and Remco van Doorn. Their work appears in journals such as Nature, Pigment Cell & Melanoma Research, Cancer Cell, Cancer Research and Nature Cell Biology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.